Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ ( glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus | Business Wire
Ready-To-Use Glucagon Rescue Pen
Xeris Pharma Announces FDA to Review NDA for Its Ready-to-Use Glucagon Rescue Pen | dLife
Next-Gen Emergency Glucagon: Xeris to the Rescue? | Type one diabetes, Diabetes supplies, Diabetes
Xeris | diaTribe
Glucagon Rescue Meds and PocketCard - Diabetes Education Services
A Demand for Better Glucagon Products and Policy
Zegalogue: A New Easy-to-Use Diabetes Rescue Glucagon
Coming Soon: Generic Glucagon Rescue
Xeris: Looking For Entry Before PDUFA (NASDAQ:XERS) | Seeking Alpha
S-1/A
Xeris' glucagon injection Gvoke gains heat with HypoPen auto-injector launch | FiercePharma
Next-Gen Emergency Glucagon: Xeris to the Rescue? | Diabetes technology, Diabetes diet plan, Diabetes management
Xeris: Preparing For The Gvoke PDUFA (NASDAQ:XERS) | Seeking Alpha
Xeris' severe low blood sugar pen gets FDA approval -
FDA OKs Ready-To-Use Gvoke Glucagon By Xeris
S-1
Two New Glucagon Formulations Await FDA Approval in 2019 — Healthy Living Medical Supply
Ready-to-Use Glucagon Rescue Pen Under FDA Review for Severe Hypoglycemia Tx - MPR
How To Use Gvoke HypoPen® (glucagon injection) & Gvoke® PFS (glucagon injection)
Xeris Pharma's Gvoke: Strong Approval Chances, But This Is A Highly Competitive Space (NASDAQ:XERS) | Seeking Alpha
xeriscanaccordaug2018fin
Glucagon Rescue Meds and PocketCard - Diabetes Education Services
